Allogene Therapeutics prices IPO at $18, the high end of the range

Shutterstock photo

Allogene Therapeutics, a Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, raised $288 million by offering 16 million shares at $18, the high end of the range of $16 to $18. Allogene Therapeutics plans to list on the Nasdaq under the symbol ALLO. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as lead managers on the deal.

The article Allogene Therapeutics prices IPO at $18, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?